Non-pharmacologicaltreatment forCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeDrug classthatrevolutionizedCMLtreatmentThe scoringsystem usedin chronicphaseI have theT315I mutationbut also haveelevated lipaseToo many ofthese bloodcells areabnormal inCMLWhen togive H2RAswithdasatinibTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextPatients havepresence of thisBCR-ABLproteinindicative ofCML I want toavoid thisTKI if I donot wantdiarrheaThe numberof distinctclinicalphases inCML60-70% ofpatients withCML presentwith thissymptomTKIs aremajorsubstratesfor this liverenzymeThe current5-yearoverallsurvival rateof CMLModerateto highemetogenicrisk TKIsTreatmentfor blastphaseCMLTherecommendedcriteria usedfor acceleratedphaseResponsewhen BCR-ABL1 (IS)is <0.01%I avoid thisdrug classwith bosutinib,nilotinib anddasatinibNumber ofblastspresent inacceleratedphasePercentageof blastspresent inthe blastphaseNon-pharmacologicaltreatment forCMLAfter 3months, I have3% BCR-ABL,I have this TKIresponseThelandmarkfor thefirst TKIThis TKI hasthe mostmetabolicsyndromeDrug classthatrevolutionizedCMLtreatmentThe scoringsystem usedin chronicphaseI have theT315I mutationbut also haveelevated lipaseToo many ofthese bloodcells areabnormal inCMLWhen togive H2RAswithdasatinibTranslocationbetweenthese twochromosomesoccur in CMLI failed 3lines of TKIs,I can try thisagent nextPatients havepresence of thisBCR-ABLproteinindicative ofCML I want toavoid thisTKI if I donot wantdiarrheaThe numberof distinctclinicalphases inCML60-70% ofpatients withCML presentwith thissymptomTKIs aremajorsubstratesfor this liverenzymeThe current5-yearoverallsurvival rateof CMLModerateto highemetogenicrisk TKIsTreatmentfor blastphaseCMLTherecommendedcriteria usedfor acceleratedphaseResponsewhen BCR-ABL1 (IS)is <0.01%I avoid thisdrug classwith bosutinib,nilotinib anddasatinibNumber ofblastspresent inacceleratedphasePercentageof blastspresent inthe blastphase

Chronic Myeloid Leukemia BINGO - Call List

(Print) Use this randomly generated list as your call list when playing the game. Place some kind of mark (like an X, a checkmark, a dot, tally mark, etc) on each cell as you announce it, to keep track. You can also cut out each item, place them in a bag and pull words from the bag.


1
O
2
I
3
G
4
O
5
N
6
B
7
N
8
N
9
G
10
G
11
O
12
B
13
B
14
O
15
G
16
I
17
I
18
G
19
I
20
N
21
B
22
I
23
O
24
B
  1. O-Non-pharmacological treatment for CML
  2. I-After 3 months, I have 3% BCR-ABL, I have this TKI response
  3. G-The landmark for the first TKI
  4. O-This TKI has the most metabolic syndrome
  5. N-Drug class that revolutionized CML treatment
  6. B-The scoring system used in chronic phase
  7. N-I have the T315I mutation but also have elevated lipase
  8. N-Too many of these blood cells are abnormal in CML
  9. G-When to give H2RAs with dasatinib
  10. G-Translocation between these two chromosomes occur in CML
  11. O-I failed 3 lines of TKIs, I can try this agent next
  12. B-Patients have presence of this BCR-ABL protein indicative of CML
  13. B-I want to avoid this TKI if I do not want diarrhea
  14. O-The number of distinct clinical phases in CML
  15. G-60-70% of patients with CML present with this symptom
  16. I-TKIs are major substrates for this liver enzyme
  17. I-The current 5-year overall survival rate of CML
  18. G-Moderate to high emetogenic risk TKIs
  19. I-Treatment for blast phase CML
  20. N-The recommended criteria used for accelerated phase
  21. B-Response when BCR-ABL1 (IS) is <0.01%
  22. I-I avoid this drug class with bosutinib, nilotinib and dasatinib
  23. O-Number of blasts present in accelerated phase
  24. B-Percentage of blasts present in the blast phase